Nabla Bio

Nabla Bio is a private, pre-clinical stage biotech leveraging an integrated AI and wet-lab platform to design novel antibodies and multispecific biologics. Its core technology, the JAM generative modeling system, is trained on massive protein data and refined with proprietary human-relevant assays to enable epitope-precise, de novo drug design. The company operates a platform-plus-partnership business model, collaborating with pharmaceutical partners while advancing its own pipeline, and is positioned to tackle historically difficult drug targets like GPCRs and ion channels.

Integrated generative AI (JAM/JAM-2 system) and high-throughput human-relevant wet-lab testing for de novo design of antibodies and multispecific biologics.

Nabla Bio competes in the rapidly evolving AI-driven drug discovery sector against companies like Absci, Generate Biomedicines, and Big Pharma internal efforts. Its differentiation lies in the tight integration of generative AI with proprietary, human-relevant wet-lab data generation, aiming for a closed-loop design system rather than a screening or optimization tool.